Novo Nordisk unwraps phase 3 hemophilia A data, revealing how Roche rivalry may shake out

Novo Nordisk has shared a closer look at phase 3 results on its hemophilia A candidate Mim8, revealing new data that show how it squares up against Roche’s blockbuster Hemlibra on key measures of efficacy and tolerability.